Quipt Home Medical Announces Record Preliminary Fourth Quarter 2021 Results and Provides a Business Update

3 years ago

CINCINNATI, Dec. 16, 2021 (GLOBE NEWSWIRE) -- Quipt Home Medical Corp. (“Quipt” or the “Company”) (NASDAQ:QIPT; TSXV:QIPT), a U.S. based…

Emergent BioSolutions Announces Initiation of Phase 1 Study Evaluating Its Universal Influenza Vaccine Candidate

3 years ago

GAITHERSBURG, Md., Dec. 16, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced the first participant dosed in…

ProMIS Neurosciences Issues Chairman’s Memorandum

3 years ago

TORONTO, Ontario and CAMBRIDGE, Mass., Dec. 16, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology…

Avalo Therapeutics to Host Virtual Investor Day on January 6, 2022

3 years ago

WAYNE, Pa. and ROCKVILLE, Md., Dec. 16, 2021 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a leading clinical-stage precision…

Quipt Announces That It Anticipates a Temporary Delay in the Filing of Financial Statements and Application for Management Cease Trade Order

3 years ago

CINCINNATI, Dec. 16, 2021 (GLOBE NEWSWIRE) -- Quipt Home Medical Corp. (“Quipt” or the “Company”) (NASDAQ:QIPT; TSXV:QIPT), a U.S. based…

XOMA Announces Evolution of Company Leadership and Succession Planning

3 years ago

Chief Executive Officer Jim Neal appointed as Chairman; Former Chairman W. Denman Van Ness to remain Lead Independent Director Company…

Singular Genomics Launches the G4 Sequencing Platform

3 years ago

– Next-generation sequencing platform will provide up to three times more data output per hour than other benchtop instruments, while…

uniQure Announces Clinical Update on First Patients in Phase I/II Clinical Trial of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease

3 years ago

~ Treatment was well tolerated with no significant safety issues related to AMT-130 in first two treated patients through one…

NeuroPace to Present at 40th Annual J.P. Morgan Healthcare Conference

3 years ago

MOUNTAIN VIEW, Calif., Dec. 16, 2021 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on…

Cerevel Therapeutics and Herophilus Announce Collaboration to Evaluate Novel Neuroimmune Modulating Therapeutic Strategies for Schizophrenia

3 years ago

Companies will utilize cutting-edge brain organoids and advanced multi-modal “deep phenotyping” approach designed to enable the development of therapies with…